Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2267668 | 0.77 | — | — | |
| SCHEMBL3079555 | 0.69 | LMNA (0.38) | LMNATRPA1PTGS1CACNA1C | |
| SCHEMBL10547149 | 0.67 | LMNA (0.37) | LMNATRPA1PTGS1CACNA1C | |
| SCHEMBL25229039 | 0.67 | TRPA1 (0.46) | LMNATRPA1PTGS1CACNA1C | |
| SCHEMBL1532606 | 0.67 | CYP3A4 (0.37) | LMNATRPA1PTGS1CACNA1C | |
| SCHEMBL21023213 | 0.67 | LMNA (0.48) | LMNATRPA1PTGS1CACNA1C | |
| SCHEMBL20987638 | 0.67 | LMNA (0.54) | LMNATRPA1PTGS1CACNA1C | |
| SCHEMBL2270894 | 0.67 | MAPT (0.37) | — | |
| SCHEMBL18461006 | 0.65 | IDO1 (0.33) | LMNATRPA1PTGS1 | |
| SCHEMBL728304 | 0.65 | L3MBTL1 (0.44) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10947214-B2 | TLR7/8 antagonists and uses thereof | MERCK PATENT GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| US-20180037570-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037570-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | LMNA 1770/4885TRPA1 346/4885PTGS1 1940/4885 |
| US-10947214-B2 | TLR7/8 antagonists and uses thereof | TLR7, TLR8, TLR9 | LMNA 1770/4885TRPA1 346/4885PTGS1 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.